新型微流控快速药敏试验对革兰阴性菌血流感染的多中心评估
在四个实验室评估QuickMIC微流控线性梯度快速药敏试验,与肉汤微量稀释法比较,检测411份加标血培养和148份临床血培养及12种面板抗生素。总体基本一致率和分类一致率分别为95.6%和96.0%,室间重现性98.9%,平均分析时间3小时13分钟。结论认为QuickMIC可直接从血培养快速测定MIC,重现性、精密度和准确度高。
要点
- QuickMIC与BMD总体基本一致率95.6%,分类一致率96.0%。
- 极重大错误率1.0%,重大错误率0.6%,次要错误率2.4%。
- 平均仪器分析时间3小时13分钟,室间重现性98.9%。
核心结论
- QuickMIC可直接从血培养快速测定MIC,在临床环境中具有高重现性、精密度和准确度。
- 微流控产生的线性梯度确保实验室间高重现性,使单次检测的MIC值可信度高,但测量范围较BMD缩小。
研究设计与样本
- 在四个不同实验室评估QuickMIC的性能,并与肉汤微量稀释法(BMD)比较。
- 检测加标血培养(n=411)和临床血培养(n=148)的QuickMIC革兰阴性菌面板12种抗生素,每个站点运行10株定义菌株测量重现性。
- 应用逻辑回归和线性回归分析探索影响检测性能的因素。
主要发现
- QuickMIC与BMD的总体基本一致率为95.6%,分类一致率为96.0%。
- 极重大错误率、重大错误率和次要错误率分别为1.0%、0.6%和2.4%。
- 使用±1倍稀释可接受标准,站点间重现性高达98.9%。
- 平均仪器内分析时间总体为3小时13分钟(SD:29分钟)。
- 回归分析表明QuickMIC对初始接种量和血培养阳性后延迟时间具有稳健性。
关键数值与推荐
- 总体基本一致率95.6%,分类一致率96.0%。
- 极重大错误率1.0%,重大错误率0.6%,次要错误率2.4%。
- 室间重现性98.9%(±1倍稀释标准)。
- 平均分析时间3小时13分钟(SD:29分钟)。
临床怎么用
- QuickMIC可用于临床环境中直接从血培养快速测量MIC,帮助减少指导治疗的时间。
- 可能允许早期降阶梯广谱经验性治疗,以及在覆盖不足时快速调整治疗。
局限性
- 与BMD相比测量范围缩小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Common phenotypic methods for antimicrobial susceptibility testing (AST) of bacteria are slow, labor intensive, and display considerable technical variability. The QuickMIC system provides rapid AST using a microfluidic linear gradient. Here, we evaluate the performance of QuickMIC at four different laboratories with regard to speed, precision, accuracy, and reproducibility in comparison to broth microdilution (BMD). Spiked (n = 411) and clinical blood cultures (n = 148) were tested with the QuickMIC Gram-negative panel and compared with BMD for the 12 on-panel antibiotics, and 10 defined strains were run at each site to measure reproducibility. Logistic and linear regression analysis was applied to explore factors affecting assay performance. The overall essential agreement and categorical agreement between QuickMIC and BMD were 95.6% and 96.0%, respectively. Very major error, major error, and minor error rates were 1.0%, 0.6%, and 2.4%, respectively. Inter-laboratory reproducibility between the sites was high at 98.9% using the acceptable standard of ±1 twofold dilution. The mean in-instrument analysis time overall was 3 h 13 min (SD: 29 min). Regression analysis indicated that QuickMIC is robust with regard to initial inoculum and delay time after blood culture positivity. We conclude that QuickMIC can be used to rapidly measure MIC directly from blood cultures in clinical settings with high reproducibility, precision, and accuracy. The microfluidics-generated linear gradient ensures high reproducibility between laboratories, thus allowing a high level of trust in MIC values from single testing, at the cost of reduced measurement range compared to BMD. IMPORTANCE: Increasing antimicrobial resistance underscores the need for new diagnostic solutions to guide therapy, but traditional antimicrobial susceptibility testing (AST) is often inadequate in time-critical diseases such as sepsis. This work presents a novel and rapid AST system with a rapid turnaround of results, which may help reduce the time to guided therapy, possibly allowing early de-escalation of broad-spectrum empirical therapy as well as rapid adjustments to treatments when coverage is lacking.
引用
- Berinson B, Davies E, Torpner J, et al. A multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections. J Clin Microbiol. 2024. PMID: 39324811. doi:10.1128/jcm.00458-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。